Highlights Newsletter 3
This newsletter presents you the following key sessions:
1. Video-interview with Tait D. Shanafelt, MD, PhD who highlights the importance of the randomized phase III
trial of ibrutinib + rituximab versus standard chemoimmunotherapy for untreated CLL patients
2. Adding daratumumab to lenalidomide-dexamethasone significantly delays disease progression and increases
the response rate in patients with transplant-ineligible newly diagnosed multiple myeloma
3. Longer-term JULIET data validate the durable responses with tisagenlecleucel in adults with relapsed and
refractory diffuse large B-cell lymphoma
4. Reduced red blood cell transfusion dependence with luspatercept in patients with beta thalassemia
5. Clinical superiority of fixed duration treatment with venetoclax and rituximab over bendamustine-rituximab
in patients with relapsed/refractory chronic lymphocytic leukemia